Komori
Ono Pharmaceutical (4528) · PolicyRestated

Changes in the recognition of license income and other revenue following the adoption of IFRS 15

First written in FY2019-Q1. 2 of 3 entries say "Restated". Latest entry: FY2019-Q3.

3entries
2years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseRestatedFY2019-Q1 – FY2019-Q32018: 220182019: 12019
Same theme, other companies

1 other company's latest entry also says "Restated".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Full recordFilings, disclosures and news, newest first
  1. FY2019-Q3RestatedAnnual report

    「In the condensed interim consolidated income statement for the nine months ended the third quarter, compared with applying the previous accounting standard, revenue, cost of sales, operating profit and interim profit before tax increased by ¥8,297 million, ¥8,269 million, ¥28 million and ¥28 million, respectively.」

    The application of IFRS 15 continued, with the amounts affecting revenue, expenses and operating profit for the nine months ended the third quarter disclosed against the previous standard.
  2. FY2019-Q2RestatedAnnual report

    「In the condensed interim consolidated income statement for the six months ended the second quarter, compared with applying the previous accounting standard, revenue and cost of sales increased by ¥5,145 million and ¥5,183 million, respectively, while operating profit and interim profit before tax decreased by ¥38 million each.」

    The application of IFRS 15 continued, with the amounts affecting revenue, cost of sales and operating profit for the six months ended the second quarter disclosed specifically against the previous standard.
  3. FY2019-Q1First statedAnnual report

    「Beginning with the first quarter of the current fiscal year, the Group has applied IFRS 15, Revenue from Contracts with Customers, and Clarifications to IFRS 15. Based on the five-step approach described above, the timing of revenue recognition for license income, including upfront payments received under license agreements, was reviewed in light of the satisfaction of performance obligations. As a result, upfront payments under license agreements that had previously been deferred and recognized as revenue over a specified period are now recognized as revenue at the point when development rights, marketing rights and other rights are granted.」

    IFRS 15 was adopted from the current quarter, changing the recognition of upfront payments, milestones and other amounts under license agreements to reflect when performance obligations are satisfied. At adoption, retained earnings increased by ¥4,127 million, and current-quarter revenue was reported as ¥2,519 million higher than under the previous accounting standard.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
Ono Pharmaceutical's next results are scheduled for 2026-10-29. Read the earnings preview
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Changes in the recognition of license income and other revenue following the adoption of IFRS 15 | ONO PHARMACEUTICAL CO.,LTD. (4528) | Komori